A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
299actual
Sites
110
Countries
Australia, Canada, India +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-18 | actual | When the study began enrolling |
| Primary completion | 2025-09-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-13 | actual | The whole study's end, after follow-up |
| First posted | 2024-03-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Interventions
- Drug: NNC0519-0130
- Drug: Placebo
- Drug: Trizepatide
Primary outcome
what the primary-completion date above is the date OFChange in Glycated haemoglobin (HbA1c)
measured From baseline (week 0) to 12 weeks on a given maintenance dose
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed